This is a paid advertisement on behalf FendX Technologies Please refer to “Forward-Looking Statements and Legal Disclaimers” at the bottom of our featured report for important information.
INVESTOR ALERT:
Discover how nature’s ultimate non-stick surface is being used by FendX Technologies Inc. (FDXTF:OTCQB, FNDX:CSE, E8D:FSE) to create products that protect surfaces from contamination that could make our lives safer.
In the following report, you’ll discover why the growing antimicrobial coating industry could be a key opportunity for investors…
Tickers:
FDXTF:OTCQB
FNDX:CSE
E8D:FSE
FendX Technologies (FDXTF:OTCQB, FNDX:CSE, E8D:FSE) is pioneering a potential breakthrough in the antimicrobial surface coating market.
Inspired by the hydrophobic lotus leaf, it has a unique topography that consists of nanoscopic wrinkles that are at least a billion times smaller than we can see with the naked eye.
Only this technology doesn’t just repel water… in the lab, it’s shown to repel bacteria and viruses.
The discovery was originally made by scientists at the famed McMaster University.
It’s been detailed in several academic journals, including the prestigious ACS Nano. And it’s backed by a growing patent-pending portfolio.
It’s also been featured on major news and media outlets such as CNN Health, CBC, and Science Daily:
Now, to be clear, this nanotechnology is still in the development phase.
Lab tests at McMaster have been successful. Prototypes have been produced. And FendX’s lead product, REPELWRAP™ film, is now with its manufacturing partner who is doing further work to assess how to scale-up development of the film.
It’s not yet available on the market – there’s still work to be done. But think of the potential if it’s successful…
We’re talking about a nanotechnology that could be deployed all over the world.
It could make life safer for you, your children, the elderly, and millions of others.
And as an investor, it commands your immediate attention.
Why You Need to Pay Attention to FendX
Viruses and bacteria are all around us…
On door handles, grocery carts, store checkout stations, payment machines, bathroom sinks/taps, railings, elevator buttons and more.
They cling, grow and thrive on everyday surfaces like glass, paper, and metal.
And they can survive for days… weeks… even months unless disinfected.
Studies have shown that:
These illnesses are all potentially lethal.
Controlling their spread – as well as the spread of other bacteria and viruses – is a global initiative as current disinfecting and hygiene practices are not proving to be enough to manage it.
That’s why there is a need for additional innovative solutions to help to reduce the spread of potentially lethal bacteria and viruses.
And why scientists at McMaster University in Canada, who invented the nanotechnology inspired by the Lotus Leaf (which is licensed by FendX), believe they may have found an answer.
FendX is using their licensed nanotechnology to develop both film and spray coatings to protect high-touch surfaces that are prone to contamination, especially in healthcare and potentially other high traffic venues like schools and transportation.
Their first product in development, REPELWRAP™ film, has been shown in McMaster’s lab to instantly protect against pathogen transmission by preventing bacteria and viruses from sticking to it surface. In fact, it’s ability to safeguard against the spread of potentially deadly pathogens is nothing short of impressive:
REPELWRAP™ film reduces the amount of infectious viral particles for Covid-19 -like viruses by more than 99%…and reduces the formation of bacterial colonies like MRSA and pneumonia-causing Pseudomonas aeruginosa by more than 85%. .[7,8]
REPELWRAP™ film is currently with FendX’s manufacturing partner who is gearing up to do their first automated small-scale runs on their commercial manufacturing line to create intermediate size film samples for testing.
FendX is also working on a spray-on version of this repel technology.
When sprayed onto a surface, it forms a protective film coating similar to REPELWRAP™ film with the same repelling properties.
It also has a secondary benefit in that it effectively inactivates residual pathogens on the coated surface.
As well, a potential spray product could be easier to apply to many surfaces and may expand potential market applications.
FendX is collaborating with McMaster to further develop the spray nanotechnology as we speak.
But that’s not all…
FendX is also exploring additional applications of their nanotechnology, including development of enhancements to the current REPELWRAP™ film to create follow-on films including films with both repelling and killing properties.
FendX also plans to assess the nanotechnology to develop a coating for catheters to prevent catheter-related blood clot or bacterial colony formation which are known to cause occlusion in long-term use catheters.
To date, FendX in collaboration with McMaster are in early-stage research to assess these additional applications. But FendX believes they will be important additions to the current projects as they may provide expanded applications of their nanotechnology.
As an investor, you might want to pay close attention to FendX (FDXTF:OTCQB, FNDX:CSE).
FendX’s REPELWRAP™ film offers instant, 24-7 protection without the need for continuous disinfecting.
You see, one of the biggest differences is that other antimicrobial coatings require viruses and bacteria to attach to their surface to be killed. Once attached, it can take time for these pathogens to be neutralized which means they have the potential to be passed on – before they are killed – to unsuspecting individuals when they touch the surface.
This creates a “window of transmission” where contaminated surfaces can be hot spots for spreading potential lethal bacteria and viruses – especially in high-traffic touch point areas.
In contrast, FendX’s REPELWRAP™ film’s nano-scale engineering creates a surface that pathogens can’t attach to.
Since pathogens can’t attach, they can’t replicate and create colonies to be passed on.
This means that if a REPELWRAP™ film-coated surface is touched with a contaminated hand, there is a small chance for this contamination to stick and spread.
1) It significantly reduces the transfer of deadly pathogens like MRSA, E-Coli, COVID-19 related viruses.
2) It works instantly.
3) It offers 24-7 protection.
4) And it has numerous potential opportunities in high-impact markets, including healthcare and other high traffic industries.
Handrails… Doorknobs… Countertops… Medical Equipment…
The Market Potential of Antimicrobial Protective Coatings is Huge
Future Markets Inc. estimates the antimicrobial coatings market size will TRIPLE IN SIZE to $11 billion in 2027, up from $3.7 billion in 2022. [9]
FendX has the potential to enter this antimicrobial coating market (should REPELWRAP™ film successfully achieve developmental scale-up to larger sizes and their spray formulation achieve similar objectives).
A key reason why there is a potentially huge opportunity for antimicrobial coatings in healthcare settings is because about 1-in-31 hospital patients get a healthcare-associated infection (HAI). [10]
That’s a huge number of people being exposed to harmful pathogens in what’s “supposed” to be considered a safe environment.
In fact, HAI’s are one of the top 10 leading causes of death in the world.[11]
These are staggering statistics. So how does it happen?
According to the National Health Institute, contact transmission – when an infected patient comes in direct contact with another individual or contaminates a surface like a doorknob or handrail – is the one of the major modes of transmission in the health care setting. [13]
The direct medical costs associated with these infections are massive, totaling at least $28.4 billion each year. They also account for an additional $12.4 billion in costs to society from early deaths and lost productivity.[14]
And with new virus strains emerging and increasing antibiotic resistant bacteria, there’s a growing demand for innovative solutions to protect against their spread.
This Opportunity Should Be Added to Your Radar
Listen, FendX’s patent-pending technology has the potential to tap into a big opportunity in helping contribute to the global threat of potentially lethal bacterial and viral transmission.
Do your own research now.
Given the difficulty to control the spread of pathogens…
Our heightened awareness of the potential seriousness of infections caused by pathogens…
And the growing potential threat of healthcare-associated infections…
Investors would be wise to closely evaluate FendX Technologies Inc. (FDXTF:OTCQB, FNDX:CSE) as potential future key player in the race to reduce the spread of bacteria and viruses.
Talk to your broker today.
6 Reasons to Consider FendX Technologies Inc. (FDXTF:OTCQB, FNDX:CSE, E8D:FSE):
1) Nanotechnology with Repelling Properties:
FendX’s nanotechnology, inspired by the water-resistant lotus leaves, consists of nanoscopic wrinkles that are a billion-times smaller than what can be seen with the human eye.
These wrinkles create a unique topography that bacteria, viruses – almost anything – can’t stick to. It works instantly and offers 24-7 protection, addressing the growing need for new products to contribute to continuous protection of surfaces prone to contamination to reduce the spread of bacteria and viruses.
Global infections continue to be difficult to control despite efforts to contain their spread. This is increasing the demand for innovative and effective infection control measures.
FendX has the potential to be adopted across various high-traffic public settings such as healthcare facilities, public transportation, schools, and offices. The sheer size and diversity of the target market has the potential to present a large future growth opportunity.
3) New Spray Product in Development:
FendX is working with McMaster University to develop a spray-on version of REPELWRAP™ film using its unique nanotechnology which may prove to be easier to apply to many surfaces and may expand potential market applications.
4) Timely and Relevant:
In an era where public health and safety concerns are at an all-time high, FendX may address the needs and worries of consumers and businesses alike, potentially making it an attractive and relevant opportunity.
5) Different From Other Antimicrobial Coating Films:
FendX’s pathogen-repelling technology is different than other films on the market today.
Other films require viruses and bacteria to attach to their surface to be killed, creating a potential “window of transmission” where bacteria or viruses on the film can still be spread.
FendX uses nanoscale engineering to create surfaces that pathogens can’t attach to. Since pathogens can’t attach, they’re hard to pass on.
6) Future, Untapped Industries May Add Potential:
FendX’s nanotechnology has the potential to be applied to other types of surfaces and materials – such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters.
Underserved markets like this offer potential future upside if the company can successfully adapt their nanotechnology.
Put FendX Technologies (FDXTF:OTCQB, FNDX:CSE) on Your Radar Today!
If you still have questions, contact our Investor Relations Team
You can also download a free investor information package below:
By requesting an investor information package, you agree to our Privacy Policy & Terms, and agree to receive periodic emails from Investing Insider and our partners. You can opt out at any time.
FendX Technologies Inc General Disclaimer
This article contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface and coating market, overall market growth rates and the Company’s growth rates and growth strategies; that the frequency of common infections spread by touch, microbe repellent technology is a promising, high-growth industry; the use of available funds; the performance of the Company’s business and operations; the Company’s expectations regarding revenues, expenses and anticipated cash needs; the intention to grow the Company’s business and operations; the expected timing and completion of the Company’s near-term objectives; laws and regulations and any amendments thereto applicable to the Company; the Company’s competitive advantages and business strategies; the Company’s future product offerings, including potential new applications (i.e. catheters) and new formulations (i.e. spray); the Company’s research and development initiatives and expected results thereof; the Company’s growing patent portfolio; the Company entering into distribution, manufacturing and other business relationships, in Canada, the United States, and globally; the potential of the Company’s technology to protect against the spread of pathogens on surfaces through repelling bacteria and viruses that come in contact with its surface; that the Company’s technology will bring significant value in controlling the spread of surface borne infectious diseases; trends regarding healthcare-acquired infections; proprietary REPELWRAP™ film could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; the Company’s nanotechnology has the potential to be applied to other types of surfaces and materials –such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like this offer potentially future upside, if the Company can successfully adapt their technology; the Company’s intention to initially target REPELWRAP™ film towards healthcare settings and high traffic public touchpoints; that as the Company continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, education, sports and entertainment sectors; the growing global commitment to reduce the spread of pathogens; the development of the Company’s spray nanotechnology, which could be easier to apply to many surfaces and expand potential market applications; the Company’s organic growth strategy and expansion strategy; line extensions for REPELWRAP™ film; further development of core technology into additional applications (i.e. catheters); expansion into vertical markets; licensing of additional nanotechnology formulations and/or complementary products that reduce pathogen spread; potential licensing, M&A and partnerships within the infectious disease space; and that REPELWRAP™ film will provide additional protection to current disinfecting practices to control the spread of pathogens.
Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement, Spray License Agreement and Collaborative Research Agreements between the Company and McMaster University and maintaining licenses in good standing; inability of McMaster University to satisfy the terms under the License Agreement, Spray License Agreement and Collaborative Research Agreements; ability to successfully complete of scale-up and development of commercial film, spray and other products; research and development activities; reliance on grant funding; limited number of products; dependence on collaborative partners, licensors and others; no formal manufacturing or distribution agreements in place; changes and restrictions due to legal and regulatory requirements; dependence on each product’s acceptance in the market; possibility of smaller market opportunities than anticipated; increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of the Company’s directors and officers; management’s efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of the Company’s common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavorable research about the Company; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; use of available funds; effect of general economic and political conditions; internal controls; and other risk factors and potential effects set forth in the Company’s public filings, publicly available through the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedarplus.ca for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any Forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement.
While the information contained in this presentation is believed to be accurate, the Company expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this presentation or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this presentation are intended to be, nor shall be deemed to be, representations or warranties of the Company. Where the information is from third-party sources, the information is from sources believed to be reliable, but the Company has not independently verified any of such information contained herein.
This presentation is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any securities.
[1] https://www.cnn.com/2019/12/13/health/superbug-repelling-surface-intl-scli-scn/index.html
[2] https://www.cbc.ca/radio/quirks/feb-15-agriculture-moving-north-arrokoth-s-secrets-the-microbiome-for-flight-and-more-1.5463847/canadian-scientists-engineer-self-cleaning-surface-that-can-repel-dangerous-bacteria-1.5463857
[3] https://www.sciencedaily.com/releases/2019/12/191213123554.htm
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394922
[5] https://www.bbc.com/future/article/20200529-the-surfaces-that-kill-bacteria-and-viruses
[6] https://www.cnbc.com/2020/10/12/virus-that-causes-covid-19-can-survive-for-28-days-on-surfaces-research-says.html
[7] https://fendxtech.com/repelwrap/
[8] https://cosmosmagazine.com/technology/materials/repelwrap-repels-viruses/
[9] Future Markets Inc., January 2023
[10] https://www.cdc.gov/policy/polaris/healthtopics/hai/index.html
[11] https://www.who.int/news/item/06-05-2022-who-launches-first-ever-global-report-on-infection-prevention-and-control
[12] https://askwonder.com/research/total-number-high-schools-also-known-secondary-schools-universities-known-j4lribx4j
[13] https://www.ncbi.nlm.nih.gov/books/NBK2683/
[14] https://www.cdc.gov/policy/polaris/healthtopics/hai/index.html
Download a free investor information package
Simply fill out the form below:
By requesting an investor information package, you agree to our Privacy Policy & Terms, and agree to receive periodic emails from Investing Insider and our partners. You can opt out at any time.
FEATURED NEWS:
VIDEO:
VIDEO:
FENDX RECENT NEWS:
January 24, 2023
December 13, 2023
November 29, 2023
November 1, 2023
October 26, 2023
October 3, 2023
July 20, 2023
June 21, 2023
May 25, 2023
May 17, 2023
1 – https://finance.yahoo.com/quote/MSFT/history?p=MSFT (opening price of $243.08 on Jan3, 2023 to closing price of $430.30 on September 30, 2024)
2 – https://finance.yahoo.com/quote/META/history?p=META (opening prices of $122.82 on Jan3,2023 to cloasing price of $572.44 on Sep 30, 2024)
3 – https://finance.yahoo.com/quote/NVDA/history?p=NVDA (opening price of $14.31 on Jan3,2023 to closing price of $121.44 on Sep 30, 2024)
4 – https://www.weforum.org/agenda/2023/01/global-growth-story-of-the-21st-century-lse-grantham-systemiq-davos2023/
5 – https://www.globalbankingandfinance.com/artificial-intelligence-the-future-of-investment/
6 – https://www.pwc.co.uk/services/human-resource-services/insights/is-workforce-ready-for-ai.html
7 – https://sitn.hms.harvard.edu/flash/2020/modern-drug-discovery-why-is-the-drug-development-pipeline-full-of-expensive-failures/
8 – https://www.eidasolutions.com/the-pharmaceutical-industry-in-figures/
9 – https://vakilsearch.com/blog/what-is-the-most-profitable-pharmaceutical-drug-ever/
10 – https://www.drugdiscoverytrends.com/top-pharma-rd-spenders-2022/
11 – https://www.fiercebiotech.com/biotech/top-10-pharma-rd-budgets-2022
12 – https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html
13 – https://www.pharmaceutical-technology.com/features/featurecounting-the-cost-of-failure-in-drug-development-5813046/
14 – https://www.fiercebiotech.com/special-reports/2022s-top-10-clinical-trial-flops
15 – https://www.biospace.com/article/phase-iii-flop-ends-sanofi-s-breast-cancer-serd-candidate/
16 – https://www.fiercebiotech.com/biotech/merck-co-bails-ngm-eye-disease-collab-wake-phase-2-fail
17 – https://finance.yahoo.com/news/pfizer-cuts-stage-asset-rare-174713321.html
18 – https://ftloscience.com/process-costs-drug-development/
19 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/
20 -https://ftloscience.com/process-costs-drug-development/
21 – NetraMark Deck 2023, slide 11
22 – https://www.pfizer.com/science/clinical-trials/guide-to-clinical-trials/meet-people
23 – https://www.koreabiomed.com/news/articleView.html?idxno=21181
24 – https://www.prnewswire.com/news-releases/sanofi-accelerating-future-breakthroughs-through-clinical-trials—part-1-of-3-300647127.html
25 – https://www.statista.com/statistics/732997/number-of-registered-clinical-studies-worldwide/
26 – https://www.fiercebiotech.com/biotech/top-10-pharma-rd-budgets-2022
27 – https://www.weforum.org/agenda/2023/01/global-growth-story-of-the-21st-century-lse-grantham-systemiq-davos2023/
28 – https://eandt.theiet.org/content/articles/2023/01/money-markets-ai-is-the-investors-next-big-thing/
29 – https://www.forbes.com/sites/bernardmarr/2022/10/19/the-disruptive-economic-impact-of-artificial-intelligence/?sh=6257b0f940b7
30 – https://www.bbc.co.uk/news/business-65675027
31 – $148.51 open on January 3, 2023 to $424.13 close July 3, 2023.
32 – https://synthedia.substack.com/p/stability-ai-is-raising-funds-at
33 – https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/
34 – https://www.pharmaceutical-technology.com/features/featurecounting-the-cost-of-failure-in-drug-development-5813046/
Simply input your email below to reveal the company and ticker:
(By inputting your email below you agree to receive emails from Investing Insider. You can opt out at anytime.)
By requesting an investor information package, you agree to our Privacy Policy & Terms.
Simply input your email below to reveal the company and ticker:
(By inputting your email below you agree to receive emails from Investing Insider. You can opt out at anytime.)
By requesting an investor information package, you agree to our Privacy Policy & Terms.